新的延迟促进药物用于阻止和锁定功能治愈策略.
Eline Pellaers1, Alexe Denis, Zeger Debyser
1Molecular Virology and Gene Therapy, KU Leuven, Leuven, Flanders, Belgium.
Current opinion in HIV and AIDS
|March 8, 2024
概括
科学家们正在探索阻止和锁定策略,通过沉默潜伏的病毒储备来治愈HIV-1. 这种方法旨在通过诱导深度潜伏来实现功能性治疗,防止在治疗中断时发生病毒反弹.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 抗逆转录病毒疗法 (ART) 可以控制HIV-1感染,但不能消除潜在的储存库.
- ART 的中断会导致病毒从这些潜在储存库中反弹.
- 开发HIV-1的治愈策略需要针对潜伏的储存库.
结论:
- "阻止和锁定"战略为实现功能性HIV-1治愈提供了一个有希望的替代方案.
- 对延迟促进剂的进一步研究对于优化这种方法至关重要.
- 本综述讨论了2022-2023年科学文献中发现的延迟促进剂.
相关概念视频
Depolarizing Blockers: Mechanism of Action
1.6K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
1.6K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
451
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
451
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
420
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
420
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Depolarizing Blockers: Pharmocokinetics
325
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
325
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
565
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
565


